What CGRP Is

CGRP stands for calcitonin gene-related peptide. It is a small messenger molecule, a string of 37 amino acids, made by the body from the same gene that produces calcitonin, just spliced together differently. It is found throughout the nervous system, and importantly it is packed into the sensory nerves that carry pain signals. When those nerves fire, they release CGRP, and it acts as a powerful signal to widen blood vessels and turn up pain pathways.

CGRP works by docking onto a two-part receptor on the surface of cells. That receptor is a pairing of a protein called CLR (calcitonin receptor-like receptor) with a partner protein called RAMP1, and recent high-resolution imaging (cryo-electron microscopy) has shown in fine detail how CGRP slots into it. Understanding the exact shape of that lock-and-key is what made it possible to design drugs that block it precisely, which is the whole story of modern migraine prevention.

What CGRP Normally Does (Beyond Migraine)

Here is an important nuance that explains both how the drugs work and why safety gets watched carefully: CGRP is not a migraine molecule that happens to exist elsewhere. It is a body-wide signaling molecule with many normal jobs, and migraine is one place where it goes into overdrive.

Its best-known role is relaxing and widening blood vessels, one of the most potent vasodilators the body makes. It also helps transmit pain, drives neurogenic inflammation, influences gut motility, plays roles in bone metabolism and tissue repair, and is involved in energy balance. In the heart and circulation it appears to be protective, which is part of why blocking it long-term is studied closely.

This wide reach is why blocking CGRP is powerful for migraine but also why doctors keep an eye on effects elsewhere, for example on the gut (constipation) and on the cardiovascular system, especially with long-term use.

CGRP in a Migraine Attack

Migraine pain is generated through the trigeminovascular system, the network of sensory nerves (running from the trigeminal nerve) that wrap around the blood vessels and coverings of the brain, the meninges. These nerve endings are loaded with CGRP. During an attack, a wave of altered electrical activity across the cortex (cortical spreading depression, the likely basis of aura) and activation of these trigeminal nerves leads to a flood of CGRP release.

That CGRP surge does three things that together produce a migraine attack: it dilates the meningeal blood vessels, it triggers neurogenic inflammation around them (with help from mast cells and immune signals), and it ramps up pain transmission. The pain signal travels into the brainstem (the trigeminal nucleus caudalis) and the upper neck, where repeated bombardment produces central sensitization, the state that makes the scalp tender and light and sound unbearable. It can even feed a positive loop that keeps the attack going.

How We Know CGRP Really Matters

The case against CGRP is unusually strong for a migraine mechanism, and it rests on a few clean observations summarized in this review.

That last point is the clincher: infuse CGRP into a vein in someone who gets migraine, and you can reproduce an attack that looks just like their natural ones in roughly six out of ten people. A molecule that rises during attacks, falls when the attack is treated, and recreates the attack when given, is about as close to a smoking gun as migraine research gets. It is why blocking CGRP became the most important drug target in the field.

The Drugs That Block CGRP

There are two fundamentally different ways to interrupt CGRP, and both are now in clinics. They differ in size, how they are given, and whether they prevent attacks or stop one in progress.

Monoclonal antibodies (the "-mabs"). These are large, lab-made antibodies that lock onto CGRP itself or onto its receptor and neutralize it. Because they are big and long-lasting, they are given by injection (or one by IV) every month or every three months, and they are used purely for prevention. Four are approved: erenumab (Aimovig), which blocks the receptor, and fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti), which mop up the CGRP molecule.

Gepants (the "-gepants"). These are small molecules that block the CGRP receptor and can be swallowed as a pill or given as a nasal spray. They have evolved through three generations of chemistry to be safe for the liver and effective. Depending on the specific gepant, they are used to stop an attack (acute), to prevent attacks (daily or every-other-day), or both. Examples include rimegepant (Nurtec ODT), ubrogepant (Ubrelvy), atogepant (Qulipta), and the nasal spray zavegepant (Zavzpret).

The Drug Landscape at a Glance

A clinician-facing summary of the approved CGRP-targeted options. This is for orientation, not prescribing; the right choice depends on the individual.

Safety: What Is Known and What Is Watched

Overall, the CGRP-targeted drugs have been well tolerated, which is a big part of why they were adopted so quickly. But because CGRP does so many jobs around the body, safety is followed carefully, and the review lays out both the common, minor effects and the signals still being monitored.

The most-watched question is the cardiovascular one. Because CGRP normally protects blood vessels and the heart, there is a reasonable concern about blocking it for years, and emerging signals (including blood pressure with the receptor blocker) are being tracked, though long-term data have so far been broadly reassuring. Constipation is the most reliably reported nuisance, especially with the receptor-blocking antibody. Gepants, so far, have not thrown up major safety signals.

Beyond the Label: Real-World Signals, Including Hair Loss

The original trials were not big enough or long enough to catch every uncommon effect. Once these drugs were used by hundreds of thousands of people, safety-monitoring databases like the FDA's adverse event reporting system (FAERS) began surfacing effects that were not obvious before. These are reported associations, not proven cause and effect, but they are worth knowing because patients notice them.

Hair loss (alopecia) is the one that gets the most attention, and it is a good example of why this matters. Analyses of the FAERS database found hair loss reported across the anti-CGRP antibodies, most often with erenumab (Aimovig, the receptor blocker), and more with the antibodies than with the gepants. It was reported mostly in women, was usually non-serious, and was frequently reversible, with some people noticing it recur even after switching from one antibody to another. The hair loss is typically a diffuse shedding pattern (telogen effluvium) rather than patchy bald spots, and localized hair loss at injection sites has also been described.

The same real-world analyses flagged a few other signals not listed on the original labels, including Raynaud's phenomenon (fingers that turn cold, white, or blue), weight changes, and menstrual changes. As with hair loss, these are monitored signals, not established effects, and they fit the theme that blocking a molecule with jobs all over the body can occasionally show up in unexpected places.

CGRP Around the Body: Skin, Weight, and the Heart

Because CGRP is a body-wide molecule, its reach, and the reach of the drugs that block it, shows up far from the head. Three areas are worth understanding, and together they explain why these drugs are powerful and why their long-term effects are watched.

Skin and rosacea. CGRP, alongside substance P and PACAP, is a key driver of facial flushing and the neurogenic inflammation of the skin. That overlaps neatly with rosacea, the flushing-and-redness skin condition, which shares neurovascular and neuroinflammatory pathways with migraine and often co-occurs with it. An open question, still being studied, is whether CGRP-blocking migraine drugs might also calm rosacea, or conversely contribute to skin effects like the hair changes described above.

Weight and metabolism. CGRP plays a role in energy balance and appetite signaling. In animal studies, blocking CGRP reduced weight gain on a high-fat diet, and real-world reporting has logged weight changes among people on the antibodies. What this means in humans is not yet settled and the direction of any effect is unclear, but it is on the radar.

The heart, and why long-term blocking is watched. This is the part that ties the whole safety story together. CGRP is the most potent vasodilator the body makes, and in the cardiovascular system it is protective. In animal models, losing CGRP worsens heart failure and high blood pressure, while giving CGRP protects the heart and lowers blood pressure. That cardioprotective role is exactly why blocking CGRP for years raises a reasonable, closely monitored question about blood pressure and cardiovascular risk, even though the human data so far have been broadly reassuring. It is the clearest example of the core theme: a molecule this useful elsewhere is one you block thoughtfully.

"CGRP is a reminder that no molecule in the body has only one job. The same signal that drives a migraine attack also protects your heart and shapes your skin, which is why these drugs are powerful and why their long-term effects are followed so carefully." - Cerebral Torque

What Is Still Expanding

The CGRP story is not finished. The review highlights newer and growing uses, including vestibular migraine (the dizziness-predominant form) and, as of recent approvals, pediatric and adolescent use. Researchers are also exploring CGRP's roles well beyond the head, in bone, metabolism, the gut, and tissue repair, much of it still preclinical, which could open or constrain future uses.

"CGRP turned migraine from a condition we treated by borrowing other drugs into one with medicines designed for its actual biology. Understanding the molecule is how you understand why these treatments work and why their safety is watched so closely." - Cerebral Torque

Talking to Your Doctor

Conclusions

CGRP is a sensory-nerve signaling molecule that, in migraine, drives the vessel dilation, inflammation, and pain amplification of an attack. The evidence that it is causal, that it rises during attacks, falls with treatment, and reproduces attacks when infused, is what justified building drugs around it. Today there are two families of them: long-acting antibodies for prevention, and small-molecule gepants for acute treatment, prevention, or both, neither of which constricts blood vessels. They are generally well tolerated, with constipation and a closely watched cardiovascular question as the main caveats, and their use is still expanding into vestibular migraine and younger patients.